secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001193125-24-243481
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene raises $60M via private placement of 6.76M shares at $8.90/share
-----------------------------------------------------------------------

- Gross proceeds ~$60M from sale of 6,758,311 common shares at $8.90/share; expected close Oct 29, 2024.
- Investors include Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital, Venrock Healthcare.
- Net proceeds to fund detalimogene development, pre-commercial activities, DDX platform expansion, and working capital.
- Combined with existing cash, expected to fund operating plan into 2027.
- Leerink Partners, Piper Sandler, Guggenheim, Wells Fargo acted as placement agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312524243481/0001193125-24-243481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312524243481/d863566d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-243481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer